154 related articles for article (PubMed ID: 35032094)
21. Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.
Stevens WW; Staudacher AG; Hulse KE; Carter RG; Winter DR; Abdala-Valencia H; Kato A; Suh L; Norton JE; Huang JH; Peters AT; Grammer LC; Price CPE; Conley DB; Shintani-Smith S; Tan BK; Welch KC; Kern RC; Schleimer RP
J Allergy Clin Immunol; 2021 Feb; 147(2):600-612. PubMed ID: 32371071
[TBL] [Abstract][Full Text] [Related]
22. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease.
Aksu K; Kurt E; Alatas Ö; Gülbas Z
Allergy Asthma Proc; 2014; 35(2):148-55. PubMed ID: 24717792
[TBL] [Abstract][Full Text] [Related]
23. Aspirin-exacerbated respiratory disease and current treatment modalities.
Sakalar EG; Muluk NB; Kar M; Cingi C
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737
[TBL] [Abstract][Full Text] [Related]
24. [Cytokine profile of chronic rhinosinusitis without polyps].
Kokorina OV; Boeva VI; Apalko SV; Vologzhanin DA; Dvoryanchikov VV; Shcherbak SG
Vestn Otorinolaringol; 2022; 87(4):51-55. PubMed ID: 36107181
[TBL] [Abstract][Full Text] [Related]
25. Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
Talat R; Gengler I; Phillips KM; Caradonna DS; Gray ST; Sedaghat AR
Ann Otol Rhinol Laryngol; 2022 Oct; 131(10):1130-1136. PubMed ID: 34775833
[TBL] [Abstract][Full Text] [Related]
26. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185
[TBL] [Abstract][Full Text] [Related]
27. Cortactin expression in nasal polyps of Aspirin-Exacerbated Respiratory Disease (AERD) patients.
Brescia G; Parrino D; Nicolè L; Zanotti C; Lanza C; Barion U; Marino F; Marioni G
Am J Otolaryngol; 2018; 39(3):293-298. PubMed ID: 29534838
[TBL] [Abstract][Full Text] [Related]
28. Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis.
Stevens WW; Staudacher AG; Hulse KE; Poposki JA; Kato A; Carter RG; Suh LA; Norton JE; Huang JH; Peters AT; Grammer LC; Conley DB; Shintani-Smith S; Tan BK; Welch KC; Kern RC; Schleimer RP
J Allergy Clin Immunol; 2021 Aug; 148(2):439-449.e5. PubMed ID: 33819512
[TBL] [Abstract][Full Text] [Related]
29. Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
Lee JU; Chang HS; Lee HJ; Bae DJ; Son JH; Park JS; Choi JS; Hwang HG; Park CS
Respir Med; 2017 Feb; 123():71-78. PubMed ID: 28137499
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis: response to systemic corticosteroids.
Lennard CM; Mann EA; Sun LL; Chang AS; Bolger WE
Am J Rhinol; 2000; 14(6):367-73. PubMed ID: 11197112
[TBL] [Abstract][Full Text] [Related]
31. A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
Malfitano MJ; Santarelli GD; Gelpi M; Brown WC; Stepp WH; Hernandez S; Kimple AJ; Thorp BD; Zanation AM; Ebert CS
Am J Rhinol Allergy; 2021 Mar; 35(2):172-178. PubMed ID: 32660262
[TBL] [Abstract][Full Text] [Related]
32. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Esmaeilzadeh H; Nabavi M; Aryan Z; Arshi S; Bemanian MH; Fallahpour M; Mortazavi N
Clin Immunol; 2015 Oct; 160(2):349-57. PubMed ID: 26083948
[TBL] [Abstract][Full Text] [Related]
33. Aspirin Exacerbated Respiratory Disease and Nasal Polyp Phenotyping.
Kaboodkhani R; Bolkheir A; Esmaeilzadeh H; Faramarzi M; Ashraf M; Hosseinialhashemi M; Mortazavi N; Ebrahimi N
Iran J Pharm Res; 2021; 20(4):21-28. PubMed ID: 35194424
[TBL] [Abstract][Full Text] [Related]
34. Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.
Majeed AY; Zulkafli NES; Ad'hiah AH
Immunol Lett; 2023 Aug; 260():24-34. PubMed ID: 37339685
[TBL] [Abstract][Full Text] [Related]
35. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
36. Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Laidlaw TM; Chu DK; Stevens WW; White AA
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1462-1467. PubMed ID: 34999274
[TBL] [Abstract][Full Text] [Related]
37. The role of interleukin-33 in chronic rhinosinusitis.
Kim DK; Jin HR; Eun KM; Mo JH; Cho SH; Oh S; Cho D; Kim DW
Thorax; 2017 Jul; 72(7):635-645. PubMed ID: 27885166
[TBL] [Abstract][Full Text] [Related]
38. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
Gudziol V; Michel M; Sonnefeld C; Koschel D; Hummel T
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1487-1493. PubMed ID: 27830335
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
Haque R; White AA; Jackson DJ; Hopkins C
J Allergy Clin Immunol; 2021 Aug; 148(2):283-291. PubMed ID: 34364538
[TBL] [Abstract][Full Text] [Related]
40. IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease.
Kohyama K; Abe S; Kodaira K; Yukawa T; Hozawa S; Sagara H; Kurosawa M
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):510-6. PubMed ID: 22123380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
